Menu Back to Combination-Products-Conference


Combination products, comprising a drug, device, and/or biologic, have emerged as innovative medical products whose impact will continue to grow in the coming years. Novel drug delivery devices, plus new and anticipated technologies, such as digital technology and energy activated drugs, are driving rapid change in the regulation and development of combination products and leading to rapid expansion of novel applications to better meet patient needs. Legal and regulatory developments have improved the framework for combination product development, approval, and lifecycle management but must continue evolving to keep pace with technological change.

The Combination Products Conference will examine the recent and ongoing changes in the regulatory ecosystem for combination product development and approval, including new FDA guidances, implementation status of PDUFA VI commitments around combination products, FDA collaborative decision-making models and the maturation of internal alignment at the agency, global regulatory changes, including the EU Medical Device Regulation implementation roadmap, and the direction of global alignment efforts. In-depth treatment of digital and eHealth issues, as well as complex generics and their impact on innovator product policy and business perspectives will be featured.

In an interactive format, relevant stakeholders from regulatory agencies and industry will present the challenges and opportunities in combination product development and life cycle management. You will take away today’s best answers to these questions: How can the new legal and regulatory tools be used to best advance combination product development and approval? How can the regulatory framework for combination products be continuously improved? How can new technologies be leveraged to realize opportunities in development of new therapies to meet patient needs?

NEW! Travel Once, Learn Twice!
This year DIA's Combination Products Conference will be co-located with DIA's Complex Drug-Device Generic Combination Products meeting. Maximize your education and time by attending both! Save* $100 when you register for both events!
*You must register for both events at the same time for the discount to be applied.

Program Committee

  • Rachel SW Turow, JD, MPH
    Rachel SW Turow, JD, MPH Executive Counsel, Regulatory Law
    Teva Pharmaceuticals Ltd., United States
  • Kirsten H. Paulson, MS, RAC
    Kirsten H. Paulson, MS, RAC Senior Director, Global CMC Medical Devices
    Pfizer Inc, United States
  • Nancy  Stade, JD
    Nancy Stade, JD Partner
    Sidley Austin LLP, United States
  • John Barlow Weiner, JD
    John Barlow Weiner, JD Associate Director, Policy and Product Classification Officer, OCP, OC
    FDA, United States
  • Kim  Quaintance-Lunn
    Kim Quaintance-Lunn Vice President, Regulatory Policy, NA
    Bayer, United States
Load More

Contact us

Registration Questions?

Send Email

Co-located Meeting

Complex Drug-Device Generic Combination Products
*Save $100 when you register for both at the same time!

Digital Learning Catalog

eLearning Catalog Cover